Eli Lilly to Acquire AtaiBeckley for $2.8 Billion in Cash, Up to $1 Billion in Milestone Payments

MT Newswires Live07-16 19:03

Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $2.8 billion in cash plus potential milestone payments of up to $1.0 billion, the companies said Thursday.

Under the deal, Eli Lilly will pay $6.75 per share of AtaiBeckley plus up to $2.50 per share as a contingent value right on achievement of development and regulatory milestones, including the initiation of phase 3 trials and regulatory approvals of its mental health therapies, the companies said.

AtaiBeckley develops therapies for treatment-resistant depression and other serious mental health conditions.

The deal, already approved by the boards of both companies, is not subject to any financing condition and is expected to close in Q3, subject to approval by AtaiBeckley shareholders and regulatory approvals, the companies said.

Shares of AtaiBeckley were up more than 30% in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment